S.O.S. Drug Policy Newsletter & Legislative Updates

  • Home
  • S.O.S. Drug Policy Newsletter & Legislative Updates

DEA Moves to Temporarily Schedule 7-Hydroxymitragynine (7-OH) and Related Substances

DEA Moves to Temporarily Schedule 7-Hydroxymitragynine (7-OH) and Related Substances
The U.S. Drug Enforcement Administration (DEA) has issued two Notices of Intent to temporarily place 7-hydroxymitragynine (7-OH) and three related substances into Schedule I of the Controlled Substances Act (CSA). This temporary scheduling includes: 7-Hydroxymitragynine (7-OH), Mitragynine pseudoindoxyl (MP), Dihydro-7-hydroxymitragynine (MGM-15), and 9-fluoro derivative of 7-hydroxymitragynine (MGM-16). These substances exhibit psychoactive, opioid-like effects, have unpredictable…
Read more

Children Should Never Be the Cost of Marijuana Commercialization

Children Should Never Be the Cost of Marijuana Commercialization
A new study analyzing 25 years of poison control center data found pediatric marijuana exposures have increased dramatically since 2009. Researchers report more than a 6,000% increase among children under age six, raising important questions about cannabis commercialization, child safety, and the need for stronger public health protections.
Read more

Combating Illicit Xylazine

Combating Illicit Xylazine
Senator Ashley Moody is cosponsoring the Combating Illicit Xylazine Act to curb the spread of xylazine in the illicit drug supply while ensuring continued access for veterinary use. Learn how this legislation addresses a growing public health concern.
Read more